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Summary Background: Hepatocellular carcinoma is a common cancer with an increasing incidence worldwide because of the dissemination of hepatitis B and hepatitis C virus infection. Surgical resection is the most important therapeutic option with a curative intent. Early tumor detection through screening and improvements in surgical techniques have significantly improved the outcome of patients with hepatocellular carcinoma. However, local recurrence after curative hepatic resection is common and is the most frequent cause of death in these patients. Patients and Methods: In an attempt to identify the risk factors that predict tumor recurrence, we conducted this retrospective study in a single institution for a 6-year period. Of the 100 consecutive patients who underwent curative tumor resection, we analyzed age, sex, viral etiology (hepatitis B virus vs. hepatitis C virus), preoperative levels of aspartate aminotransferase and alanine aminotransferase, the a-fetoprotein level, underlying liver disease status (chronic hepatitis vs. cirrhosis), number and size of tumors, type of resection, and presence of microvascular invasion. Results: In the median follow-up period of 36 months (range, 12e85 months), the 1-year, 3-year, and 5-year overall survival rates were 90%, 84%, and 73%, respectively; tumor recurrence occurred in 38 (38%) patients and was the leading cause of death among the patients who died (15 of 17 patients; 88%). On univariate analysis, the only factor significantly associated with a higher incidence of tumor recurrence was preoperative levels of aspartate aminotransferase greater than twice the upper normal value (p < 0.01) and this factor remained significant with multivariate analysis. Subgroup analysis of the risk factor of early tumor recurrence ( 2 years) and late tumor recurrence
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers in Asia and Africa and its incidence is increasing worldwide because of the dissemination of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection [1] . It is prevalent in Taiwan with around 10,000 new cases each year and has been the leading cause of cancer death, accounting for approximately 8000 deaths annually [2] . Recent advances in screening, such as ultrasonography, dynamic computed tomography, and magnetic resonance imaging, have made early diagnosis possible and thus improved survival [3, 4] . Surgery is the most important therapeutic option for patients with HCC [5, 6] . With the progress in early diagnosis and operative techniques, the outcome of patients with HCC after tumor resection have significantly improved, with median survival rates of 80% (range, 63e97%) at 1 year and 50% (range, 17e69%) at 5 years, with a surgical mortality rate of less than 2% [5,7e9] . The wide ranges of survival rates are attributed mainly to differences in the HCC stage among various studies, with an obvious survival advantage in early-stage tumors [10] . However, a significant proportion of patients cannot achieve a cure or a sustained tumor-free survival and the long-term outcome after initial treatment remains unsatisfactory because of a high recurrence rate, ranging from 43% to 100% at 5 years [6,7,11e15] .
HCC recurrence has been classified as early (within 2e3 years) or late. Early recurrence is usually due to metastasis from the primary tumor (dissemination from the primary tumor), whereas late recurrence is often due to de novo second primary tumors occurring in a cirrhotic or HBVinfected liver [16] . Many factors have been identified to be associated with tumor recurrence after surgical resection, including: the accompanying chronic viral hepatitis status (Ishak activity score); serum levels of albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), a-fetoprotein, and HBV DNA; the extent of hepatectomy; and various tumor factors [12,13,16e21 ]. Among these, the most powerful predictors of recurrence are the presence of microvascular invasion or additional tumor sites besides the primary lesions, or both [12] . In this retrospective study we aimed to identify the risk factors for recurrence in patients undergoing curative surgical resection in a single institution.
Methods
We retrospectively searched the database of the Chi-Mei Medical Center in southern Taiwan for patients diagnosed with HCC who underwent curative liver resection from March 2002 to March 2008. The institutional review board approved this study. We used either ultrasonography and abdominal computed tomography (CT) scan or magnetic resonance imaging (MRI) to determine the anatomical location of HCC; the operative procedures were defined according to Couinaud's classification of hepatic segments [22] . Curative resection referred to a complete resection of all macroscopic tumors with tumor clearance along the parenchymal transection line.
We reviewed the medical records of the patients for the underlying causes of hepatitis and coexisting liver diseases. Those patients with cirrhosis were classified according to the ChildePugh scheme [23] . The clinicopathological variables evaluated included age at surgery, sex, etiology of hepatitis, a-fetoprotein level, microvascular invasion, number and size of tumors, type of resection, underlying liver disease status (chronic hepatitis vs. cirrhosis), and preoperative levels of AST and ALT. The Barcelona Clinic Liver Cancer (BCLC) classification was used for clinical staging. All patients were followed up regularly every 2e3 months after surgery. Tumor recurrence was suspected in the presence of progressive elevation of serum a-fetoprotein levels and detection of a new hepatic lesion by ultrasonography. Tumor recurrence was diagnosed by dynamic CT scan or MRI showing contrast enhancement during the arterial phase and washout in the venous phase, or hepatic angiography disclosing a high vascularity tumor. Once tumor recurrence was suspected, patients were admitted to hospital for the confirmation of diagnosis and appropriate management, including resection, local ablation treatment, transcatheter arterial chemoembolization, chemotherapy, radiotherapy, or supportive treatment. Continuous data were expressed as mean AE standard deviation and compared with the unpaired t test. Dichotomous variables were evaluated with c 2 analysis or Fisher's exact test to define various patient groups contributing significantly to the factors affecting disease-free survival and recurrence. Survival analysis was performed by the KaplaneMeier method and the difference in the curves was tested with the log-rank test. To determine prognostic factors for disease-free survival during the follow-up period, the Cox proportional hazard model was used to estimate the risk of the following potential variables: age, sex, viral etiology (HBV or HCV), a-fetoprotein level, number and size of tumors, type of resection, underlying liver 
Results
We identified a total of 113 patients receiving curative resection for HCC during this study period; 13 patients had data missing, but the remaining 100 patients were analyzed in this study. Tumor recurrence occurred in 38 (38%) patients. Seventeen patients died during the follow-up period and the causes of death included tumor recurrence (15 patients, 88%) and one patient (6%) each with intracranial hemorrhage and operative complications. The 1-year, 3year, and 5-year disease-free survival rates were 77.5%, 61.1%, and 48.6%, respectively. The survival rate between the disease-free and tumor recurrence groups was significant (p < 0.001; Fig. 1 ).
On univariate analysis, the only factor significantly associated with a higher incidence of tumor recurrence was preoperative levels of AST greater than twice the upper normal value (2N; p < 0.01). Tumor recurrence was not related to age at surgery, sex, or HBV or HCV infection, afetoprotein level, tumor size (<3 cm, 3e5 cm, or >5 cm), tumor multifocality (single vs. multiple), type of resection, underlying chronic hepatitis versus cirrhosis, or preoperative levels of ALT greater than twice the normal value ( Table 2 ). Preoperative AST level greater than twice the normal value remained significantly (p < 0.05) related to a higher incidence of tumor recurrence with multivariate analysis. Meanwhile, patients with preoperative levels of AST and ALT greater than twice the upper normal value had Fig. 2A and B ). In addition, subgroup analysis was conducted to determine the risk factor of early tumor recurrence ( 2 years; 32 patients, 84%) and late tumor recurrence (>2 years; 6 patients, 16% ) in this study. A significant correlation of high AST level and tumor recurrence, in both early and late recurrence, was noted, as shown in Tables 3 and 4 .
Discussion
The overall survival after liver resection for patients with HCC has been prolonged because of improvements in the early detection of tumors and advances in surgical techniques and perioperative care [3, 4, 6] . However, the longterm results are not satisfactory as a result of tumor recurrence, which is the main cause of mortality [11, 16, 24, 25] . Previous studies have identified that various factors, such as tumor factors and a-fetoprotein levels, are related to a high incidence of tumor recurrence [11, 13, 17, 18, 24, 26] . In our study, tumor recurrence occurred in 38% of patients and it was the leading cause of death. Both univariate and multivariate analysis showed that preoperative levels of AST greater than twice the normal value was the only factor significantly associated with a higher rate of tumor recurrence after curative surgery.
Several Japanese groups have pointed out that chronic active hepatitis and cirrhosis were the most significant risk factors for intrahepatic tumor recurrence, which probably develops through multicentric hepatocarcinogenesis, the so-called "multicentric occurrence" after hepatectomy [17, 18, 27] . This can be explained by the fact that repeated inflammation and cellular necrosis in patients with chronic hepatitis or cirrhosis enhance proliferating activity and accelerate the development of new foci of HCC through an increased rate of random mutations and promotion due to gene instability [28, 29] . Adachi et al [13] considered active inflammation as a basic cause of recurrence. They found that in livers with inflammatory changes, some adhesion molecules that adhered to cancer cells in the remnant liver after resection appeared and caused postoperative recurrence [13] . In patients with chronic hepatitis or cirrhosis, the serum aminotransferase levels are usually considered an index of inflammatory activity that reflects the etiopathogenetic mechanism of hepatocytic necrosis [30] . In keeping with these findings, we found that an elevated preoperative AST level over twice upper normal values (>2N) was the only variable closely associated with tumor recurrence. In a cohort of 244 liver resections for HCC in cirrhosis, Ercolani et al [7] identified that single nodules and preoperative AST levels less than twice the upper normal value (<2N) were related to a better 5-year diseasefree survival and lower tumor recurrence. In particular, among HCV-positive patients the recurrence rate was strongly affected by the preoperative AST level [7] . Similar results on the significance of elevated serum aminotransferase levels predicting a higher chance of recurrence, including in patients with small HCC, have also been reported by other workers [9, 17, 31] . These data indicate an important pathogenetic role of hepatic inflammation and the patients with a higher risk of recurrence may benefit from adjuvant treatments with antiinflammatory drugs to prevent tumor recurrence after liver resection. For these reasons, several workers have investigated the efficacy of interferon, an inflammationmodulating drug, for preventing the occurrence of HCC in patients with HBV-or HCV-related liver disease [26, 32, 33] .
Antiviral treatment with interferon has been recommended to prevent tumor recurrence after primary curative treatments in HCV-related HCC [5] . However, there was less evidence for antiviral treatment with nucleos(t)ide analogues to prevent tumor recurrence in HBV-related HCC [34] . The major reason for this phenomenon is that early recurrence is probably due to previously undiscovered metastasis from the primary tumor. The early recurrence accounts for most of the total number of recurrences [35] . However, a recent retrospective analysis showed a favorable result on the 1-year, 3-year, and 5-year disease-free survival rates in the early antiviral treatment group compared with those without treatment [36] . Su et al [37] also reported that antiviral treatment could decrease recurrence in patients with HBV-induced HCC after resection surgery. Our result of high preoperative ALT levels correlating with both early and late recurrences also supports the view that early antiviral treatment may contribute to the survival of patients with HCC after curative treatment, especially for those with hepatitis activity.
A limitation of our study is the small number of patients, especially when they are subdivided into three groups based on tumor size and the underlying viral etiologies or different age groups. Nonetheless, we identified a significant correlation of high AST level and tumor recurrence in both early and late recurrence. Our findings also suggest that early antiviral treatment may improve the prognosis of HBV-related HCC.
